Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 2/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.44 |
| ▸ | HTR2C | P28335 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
| ▸ | CRHBP | P24387 | 1/20 | 0.42 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4880013 | 0.90 | ALDH1A1 (0.46) | SIGMAR1ALDH1A1KDM4ELMNATSHR | |
| SCHEMBL4877607 | 0.87 | SIGMAR1 (0.42) | ADAM17SIGMAR1ALDH1A1KDM4ELMNA | |
| SCHEMBL4882566 | 0.85 | HDAC4 (0.48) | ADAM17ALDH1A1GRIN2BMEN1KMT2A | |
| SCHEMBL4872683 | 0.85 | ADAM17 (0.52) | ADAM17ALDH1A1MEN1KMT2ACRHBP | |
| SCHEMBL4877598 | 0.84 | OPRD1 (0.41) | ADAM17ALDH1A1KDM4ELMNATSHR | |
| SCHEMBL27736564 | 0.84 | ADAM17 (0.56) | ADAM17ALDH1A1MEN1KMT2AOPRD1 | |
| SCHEMBL2846322 | 0.82 | ADAM17 (0.53) | ADAM17ALDH1A1TSHRMEN1KMT2A | |
| SCHEMBL30683829 | 0.82 | ADAM17 (0.53) | ADAM17ALDH1A1TSHRMEN1KMT2A | |
| SCHEMBL5465979 | 0.81 | ALDH1A1 (0.53) | ADAM17SIGMAR1ALDH1A1MEN1KMT2A | |
| SCHEMBL5465983 | 0.81 | ALDH1A1 (0.53) | ADAM17SIGMAR1ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080096922-A1 | Novel Sulfonamide derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-04-24 | — | — | US | disclosed |
| EP-1736467-A1 | NOVEL SULFONAMIDE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2006-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096922-A1 | Novel Sulfonamide derivative | NR4A1, NR4A2, NR4A3 | ADAM17 4084/4885SIGMAR1 298/4885ALDH1A1 2899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.